Search the Newsreel

CAPR INVESTOR ALERT: Capricor Therapeutics Securities Class Action Filed; September 28, 2026 Lead Plaintiff Deadline - Kehoe Law Firm

Kehoe Law Firm has filed a securities class action lawsuit against Capricor Therapeutics (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made misleading statements by changing the statistical analysis plan …

Robbins LLP Urges CAPR Stockholders Who Lost Money Investing in Capricor Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

Robbins LLP is informing investors who lost money in Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025, and July 26, 2026, about a securities class action lawsuit. The lawsuit alleges Capricor misled investors regarding the FDA approval path for its lead product, Deramiocel, …

CAPR Investor Announcement: Capricor Therapeutics Sued on behalf of Investors to Recover Losses after Clinical Data Leads to 64% Stock Drop

Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Capricor Therapeutics, Inc. (CAPR) for securities fraud. The lawsuit alleges that Capricor made false statements regarding its lead product candidate, Deramiocel, and the integrity of its clinical data, which led to a …

J Kumar Infraprojects rises on bagging ₹334-crore order from NBCC for DTC depot in Delhi

Kaplan Fox Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Who Suffered Losses to a Securities Class Action – Deadline is September 28, 2026

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made unauthorized changes to its statistical analysis …

Capri Holdings (CPRI) Is Down 6.5% After Raising EPS Guidance Despite Kors Inventory Delays

A Dive into Capri Holdings (CPRI) International Revenue Trends and Forecasts

Did you analyze how Capri Holdings (CPRI) fared in its international operations for the quarter ending June 2026? Given the widespread global presence of this luxury retailer, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities. …

CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, September 28, 2026 Lead Plaintiff Deadline

Hagens Berman has filed a securities fraud class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR), encouraging investors who suffered substantial losses to come forward. The lawsuit alleges that Capricor made false and misleading statements about its Duchenne muscular dystrophy drug, Deramiocel, particularly concerning …

Aprea Therapeutics Inc (APRE) Earnings Forecast: Future EPS & Revenue Growth Estimates

Aprea Therapeutics Inc (APRE) has an earnings forecast score of 9.00, placing it highly within the Biotechnology & Medical Research industry. Analysts have set an average price target of $10.50, with a strong buy rating based on the consensus of 4 analysts. The company's …

Capricor to Host Rare-Disease Therapy Update Aug. 13

Capricor Therapeutics (NASDAQ: CAPR) announced it will release its second-quarter 2026 financial results after market close on Thursday, August 13, 2026, followed by a conference call and webcast at 4:30 p.m. ET. The company will discuss its financial performance and provide a corporate update, …

Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13

Capricor Therapeutics announced it will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a …

Capricor Therapeutics (NASDAQ:CAPR) Securities Class Action Notice: Investors who Lost Money when Stock Plummeted 64% are Notified to Contact BFA Law by September 28

Capral (ASX:CAA) Builds Shareholder Value Through Cash Generation and Aluminium Strategy

Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC has announced that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) and certain of its officers, alleging violations of federal securities laws. The lawsuit seeks to recover damages for investors who purchased Capricor securities …

J Kumar Infraprojects targets 15% revenue growth, ₹8,000-10,000 crore order inflow in FY27

Capri Holdings Limited (CPRI) stock price, news, quote and history

This article provides a detailed financial overview of Capri Holdings Limited (CPRI), including its current stock price, historical data, key statistics, and analyst insights. It covers the company's business segments (Michael Kors and Jimmy Choo), financial performance, and comparisons with other luxury goods companies. …

Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Contact the Firm to Learn About Their Legal Rights

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made undisclosed changes to its statistical analysis …

Capri Holdings Limited (CPRI) latest stock news and headlines

This article provides a compilation of recent news and headlines concerning Capri Holdings Limited (CPRI), a luxury fashion company. It includes updates on earnings performance, analyst ratings, stock valuation, and investor relations announcements. The news covers insights from various financial sources like Zacks, Simply …

DJ Mediaprint & Logistics Ltd is Rated Hold

Capri Holdings (CPRI) Could Be 39% Undervalued As Fresh Guidance Resets The Debate

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Capri Holdings (CPRI) has just updated investors with fresh guidance for the second quarter and full fiscal 2027. The company also released first …

Capri Holdings (CPRI) Reports Higher EPS, Is The Stock Still Cheap?

Aprea Therapeutics Inc (APRE) Stock News Today

This article from TradingKey provides current news for Aprea Therapeutics Inc (APRE), indicating its stock price as $0.650 with a 2.81% increase. It highlights that more news will be available soon. The page serves as a hub for financial information, including quotes, news, analysis, …

Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR

ClaimsFiler is alerting investors of Capricor Therapeutics (CAPR) who suffered losses exceeding $100,000 about an upcoming lead plaintiff deadline in a class action lawsuit. The lawsuit alleges that Capricor and its executives failed to disclose material information regarding changes to the statistical analysis plan …

Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Aprea Therapeutics Inc is projected to report a loss of 23 cents per share. This information is part of an earnings preview, indicating financial analysts' expectations for the company's upcoming earnings report. The full article is available to TradingView subscribers.

Earnings call transcript: G R Infraprojects posts strong Q1 2027 growth, stock slips

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor and its executives failed to disclose material …

Tangible book value per share of Capricor Therapeutics, Inc. – HAM:4LN2

This article provides the tangible book value per share for Capricor Therapeutics, Inc. (HAM:4LN2). It notes that the market for this stock on the Hamburg Stock Exchange is currently closed with no trades. The information is presented within the context of TradingView's financial data …

FMR LLC (CPRI) discloses 2.15M Capri Holdings shares in Schedule 13G/A

FMR LLC has filed an amended Schedule 13G/A, disclosing beneficial ownership of 2,151,978.73 shares of Capri Holdings Ltd (CPRI), which represents 1.9% of the company's common stock as of July 31, 2026. The filing indicates FMR LLC has sole dispositive power over all these …

G R Infraprojects Q1 Results: Earnings call audio released

State Street Corporation (NASDAQ: CAPR custodian) holds 5.9% of Capricor Therapeutics

State Street Corporation has filed a Schedule 13G, disclosing a beneficial ownership of 5.9% of Capricor Therapeutics Inc. common stock, totaling 3,397,241 shares. The filing indicates that State Street holds 3,285,634 shares with shared voting power and 3,397,241 shares with shared dispositive power, primarily …

Capri Holdings (NYSE: CPRI) sees FMR LLC report 7% ownership stake

FMR LLC and Abigail P. Johnson have reported a 7.0% passive ownership stake in Capri Holdings Ltd (NYSE: CPRI) through an amended Schedule 13G/A filing. FMR LLC beneficially owns 8,029,528.97 shares, with sole voting power over 6,874,881.48 shares and sole dispositive power over all …

Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (CAPR) Who Suffered Losses to Contact the Firm Before September 28, 2026

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Capricor Therapeutics, Inc. (CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor's stock price fell significantly after the FDA released …

CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

Hagens Berman has filed a securities fraud class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) following allegations that the company made misleading statements about its Deramiocel clinical trial data and regulatory pathway. Investors who suffered substantial losses between December 17, 2025, and July …

Indraprastha Medical Q1 Results: Net profit rises 8% YoY to ₹55.85 crore

Indraprastha Medical Corporation shares surge 9% after Q1FY27 profit rises 9%, revenue grows 11%

Capacit'e Infraprojects Nine Monthly results